RNA Splicing: A Versatile Regulatory Mechanism in Pediatric Liver Diseases

Jian-Li Zhou†, Yu-Zhen Zhao†, Shan-Shan Wang², Mo-Xian Chen³*, Shaoming Zhou¹* and Chen Chen⁴*

¹Division of Gastroenterology, Shenzhen Children’s Hospital, Shenzhen, China, ²School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China, ³Co-Innovation Center for Sustainable Forestry in Southern China, College of Biology and the Environment, Nanjing Forestry University, Nanjing, China, ⁴Department of Infectious Disease, Nanjing Second Hospital, Nanjing University of Chinese Medicine, Nanjing, China

With the development of high-throughput sequencing technology, the posttranscriptional mechanism of alternative splicing is becoming better understood. From decades of studies, alternative splicing has been shown to occur in multiple tissues, including the brain, heart, testis, skeletal muscle, and liver. This regulatory mechanism plays an important role in physiological functions in most liver diseases. Currently, due to the absence of symptoms, chronic pediatric liver diseases have a significant impact on public health. Furthermore, the progression of the disease is accelerated in children, leading to severe damage to their liver tissue if no precautions are taken. To this end, this review article summarizes the current knowledge of alternative splicing in pediatric liver diseases, paying special attention to liver damage in the child stage. The discussion of the regulatory role of splicing in liver diseases and its potential as a new therapeutic target is also included.

Keywords: alternative splicing, children, liver disease, non-alcoholic fatty liver disease, RNA sequencing, splicing-related protein

INTRODUCTION

Chronic liver disease is an increasing health burden in children and adults. Although the incidence is unclear, it is estimated that chronic liver disease has become the 11th leading cause of death among adults (Vos et al., 2016; Gao et al., 2021). In addition, many children are hospitalized due to liver diseases each year. In children and adults, nonalcoholic fatty liver disease (NAFLD) is known as a frequently appearing chronic liver disease with a complex interplay between environmental and genetic factors in industrialized countries (Vos et al., 2016; Gao et al., 2021). It is generally accepted that pediatric liver diseases, including NAFLD, chronic viral hepatitis, and other chronic liver diseases, may develop into chronic diseases, such as cirrhosis and hepatocellular carcinoma, in adults (Della Corte et al., 2016; Nobili et al., 2019). In particular, the number of liver cancer cases has increased rapidly since 1990 (Della Corte et al., 2016). In addition to liver-associated symptoms, NAFLD is related to a risk increment of diabetes (type 2) and cardiovascular disease in adults (Draijer et al., 2019). Furthermore, hepatic cholestasis and metabolic and autoimmune liver problems have been demonstrated to be the most common causes of liver failure in children, leading to liver transplantation at their final stage (Nikeghbalian et al., 2021). On the other hand, viral hepatitis, alcoholic hepatitis, and hepatocellular carcinoma are more common in adults. In both children and adults, the vast majority of patients are asymptomatic in the early stage of disease, and the prevalence of these diseases is unknown, leading to delays in diagnosis and treatment. Furthermore, because similar responses will be shown from different injuries of hepatic cells, different types of liver diseases may show similar presentations among children (Della Corte et al., 2016). Moreover, nonspecific
signs, including abdominal pain, fatigue, loss of appetite, pruritus, or hepatomegaly, can also be present among patients. Thus, prevention and early diagnosis are important to distinguish these chronic liver diseases and will lead to cost-effective treatments in pediatric settings.

Alternative splicing is the process to mediate pre-messenger RNA maturation into mRNA, by removing introns and reattaching exons (Webster, 2017). During this precise molecular process, different transcripts are assembled with the help of splice sites and associated sequences. Hence, alterations in splicing factors, such as the usage of new splice sites or enhancer sequences, as well as disruption of splicing sequences, can lead to diseases including metabolic diseases, liver diseases, cancers, and neurodegenerative diseases (Montes et al., 2019; Rahman et al., 2020). For instance, mutations in spliceosome RNA genes were detected in hepatocellular carcinoma, medulloblastoma, and chronic lymphocytic leukemia (Jimenez et al., 2018; Suzuki et al., 2019; Rahman et al., 2020). In addition, critical changes were found in the function of RNA splicing in hepatic fat metabolism of obesity (Pihlajamaki et al., 2011). Recent studies have also demonstrated alterations in the splicing machinery in inflammation, steatosis, and fibrosis in NAFLD patients and animals (Zhu et al., 2016; Gerhard et al., 2018; Del Río-Moreno et al., 2019; Hoang et al., 2019; Wang et al., 2019). In this review article, we will summarize the appearance of alternative RNA splicing in pediatric liver diseases and highlight its roles in the development and progression of these diseases (Table 1).

### COMMON LIVER DISEASES IN CHILDREN AND ADULTS AND THEIR RELATIONSHIP WITH RNA SPLICING

#### Splicing Mutations Identified in Infantile Cholestasis

Infantile cholestasis (IC) is an impairment of bile production or flow occurring in the first months of life that affects 1:2,500 live births (Pietrobattista et al., 2020). It is recognized as an important cause of chronic liver disease in infants and young children, including biliary atresia (BA) (35–41%), progressive familial intrahepatic cholestasis (PFIC) (10%), Alagille syndrome (2–6%), and other causes (Göttze et al., 2015). This paragraph will discuss the regulatory role of alternative splicing (AS) in PFIC and Alagille syndrome. The association between AS and BA will be stated later. PFIC patients diagnosed in childhood with intrahepatic cholestasis frequently progress to end-stage liver disease before adulthood (Bull and Thompson, 2018). There are three major proteins affected in PFIC, including the bile salt export pump (BSEP) encoded by \( ABCB11 \), multidrug resistance protein 3 (MDR3) encoded by \( ABCB4 \), and a membrane lipid composition protein (FIC1) encoded by \( ATP8B1 \), while three other reported proteins may be affected in PFIC patients, including tight junction protein 2 encoded by \( TJP2 \), the farnesoid X receptor (FXR) encoded by \( NR1H4 \), and myosin 5B encoded by \( MYO5B \) (Sambrotta et al., 2014; Qiu et al., 2017; Keitel et al., 2019). To date, except for \( NR1H4 \), splicing mutations have been found in other five genes associated with PFIC (http://www.hgmd.org) (Liu et al., 2010; van der Woerd et al., 2015; Khabou et al., 2016; Stenson et al., 2017; Al-Hussaini et al., 2021). In particular, FIC1 is part of the \( p \)-type adenosine triphosphatase type 4 subfamily involved in membrane phospholipid transport (Paulusma et al., 2008). This protein is found in the apical membrane of hepatocytes and is considered to be a phospholipid translocase that carries phospholipids, such as phosphatidylethanolamine (PE) and phosphatidylserine (PS), from the cisternal membrane of the outer tubule to the cytoplasmic membrane of hepatocytes. FIC1 protects the tubule membrane by maintaining plasma membrane asymmetry (Vitale et al., 2019). Previous studies systematically described 14 mutations at the exon-intron boundary of \( ATP8B1 \) and found that most of them caused aberrant splicing of its gene product (van der Woerd et al., 2015). Furthermore, this study suggested that compensatory modified U1 small nuclear RNAs (snRNA), which are complementary to the mutated donor splicing site, are highly effective in improving exon definition, implying the therapeutic potential of these mutated loci.

Furthermore, BSEP is a binding cassette transporter for adenosine triphosphate and is involved in the transfer of bile salts from hepatocytes to bile ducts, a process which is essential for maintaining the enterohepatic circulation of related bile salts (Vitale et al., 2019). Mutations in BSEP disrupt the transportation process of bile salts out of hepatocytes, resulting in increased concentrations of intracellular bile salts to damage hepatocytes (Vitale et al., 2019). Moreover, MDR3 (\( ABCB4 \)) encodes a phosphatidylcholine (PC) flippase with two transmembrane and cytoplasmic nucleotide binding domains, respectively. This protein is specifically localized at the tubular membrane of hepatocytes to mediate PC transportation from hepatocytes to bile ducts (Vitale et al., 2019). Over-expression of MDR3 increases the transport rate of fluorescein-labeled PC, but not other phospholipids. The abnormal function of MDR3 leads to the depletion of PC in the biliary tubules and elevated free hydrophobic bile acids in the space, causing damage to bile duct cells and the development of cholestasis (Henkel et al., 2019).

In addition, TJP2 is a tight junction protein that can interact with actin cytoskeletons and liver-specific tight junction proteins, such as CLDN1 and CLDN2 (Sambrotta and Thompson, 2015; González-Mariscal et al., 2019). Tight junctions are able to prevent biliary elements from leaking into the liver parenchyma. However, upon TJP2 mutation, CLDN1 failed to localize to its original position in the hepatic lobular parenchyma. This mis-localization disrupts the tight junctions, causing the leakage of bile salts with cytotoxicity into the paracellular space and resulting in damage to bile duct cells and surrounding hepatocytes (Sambrotta et al., 2014; Sambrotta and Thompson, 2015). Previous studies have reported that the mutant C. 2180>T>G caused the jump of exon 15 of TJP2 and the deletion of 32 amino acid residues in the framework (Zhang et al., 2020). Thus, this mutation can serve as potential diagnostic targets of this disease.

At last, the fifth protein is known as myosin 5B (MYO5B), identified as a molecular motor associated with actin (Vitale et al., 2019). Reports have indicated that MYO5B can interact with
RAS-associated GTP-binding protein 11A (RAB11A), in order to assist the polarization process of epithelial cells. Meanwhile, the localization of BSEP at the tubule membrane is affected by the activity of this interaction (Girard et al., 2014; Overeem et al., 2020). Mutations in this gene have been linked to microvillus inclusion body disease (MVID), which affects enterocytes, leading to reducing bile acid uptake, diarrhea, malabsorption (Van IJzendoorn et al., 2020; Overeem et al., 2020). Qiu et al. reported that three classical splicing mutations are identified from their study and this type of mutation is defined as severe mutations. Taking into consideration the interaction between MYO5B and RAB11A, the manipulation of this upstream signal transduction module may provide additional targets for therapeutic purposes. As a congenital disorder, Alagille syndrome is characterized by eye and heart abnormalities, skeletal deformities, cholestasis, and characteristic facial features (Li et al., 1997). Nearly 94% of patients have congenital cardiac diseases, and 21–31% of patients may be candidates for liver transplantation (Li et al., 1997). Currently, approximately 94% of Alagille syndrome patients have variants of JAG1, while 1–2% of patients have NOTCH2 (McDaniell et al., 2006). Both JAG1 and NOTCH2 are identified as single-channel transmembrane proteins, containing 26 and 34 exons, respectively. Specifically, the interaction between ligand JAG1 and NOTCH2 receptor requires several functional motifs, such as the C2-like domain, delta-Serate-lag2 (DSL) domain, epidermal growth factor-like (EGF-like) repeats of JAG1, and extracellular EGF-like repeats on NOTCH2 (Chillakuri et al., 2013; Kopan and Ilagan, 2009; Lindsell et al., 1995), and the mutation of this pathway identified in children with Alagille syndrome. In addition, only one NOTCH2 mutation of the splice site of exon 33 (c.5930→1G→A) was identified in the patient with Alagille syndrome, while more than 40 splicing mutations were reported in the JAG1 gene with Alagille syndrome (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=JAG1) (McDaniell et al., 2006; Chen et al., 2018). However, these mutations affect the interaction of this pathway remains to be elucidated. Nevertheless, these reported splicing mutations may serve as potential diagnostic targets for Alagille syndrome.

**Transcriptome Studies of RNA Splicing in Metabolic Liver Diseases**

Metabolic liver diseases might be the second leading cause of liver transplantation in children, including NAFLD, Wilson’s disease (WD), alpha-1 antitrypsin, and glycogen storage disease (Eliason et al., 2020). NAFLD is the most common chronic liver disease in children and adolescents worldwide, notified to be the second most common cause of liver transplantation (Goldner and Lavine, 2020). Approximately, 2.6–11.3% of children and approximately 40–70% of obese children are diagnosed with NAFLD worldwide (Goldner and Lavine, 2020). Consequently, NAFLD affects public health, especially children and adolescents.

Several genetic variants, including genes encoding transmembrane 6 superfamily member 2 (TM6SF2), patatin-like phospholipase domain-containing 3 (PNPLA3), glucokinase regulator (GCKR), and membrane bound O-acyl transferase 7 (MBOAT7), contribute to the risk of NAFLD, whereas protein phosphatase 1 regulatory subunit 3B (PPP1R3B) has been documented to have a protective effect against NAFLD (Valenti et al., 2010; Santoro et al., 2012; Kozlitina et al., 2014; Mancina et al., 2016; Dongiovanni et al., 2017; Sheldon et al., 2016). NAFLD affects public health, especially children and adolescents.

| TABLE 1 | Studies reporting alterations of RNA splicing in pediatric liver diseases. |
|---|---|---|
| Splicing mutations in ATP8B1 of PFIC | The effect of premessenger RNA splicing on 14 ATP8B1 exon-intron boundary mutations was studied using an in vitro microgene system | van der Woerd et al. (2018) |
| Splicing variant in JAG1 | The candidate variants were verified by Sanger sequencing, and the splicing effect of the candidate variants was clarified by RNA detection | Chen et al. (2020) |
| The FXR splicing through transcriptional program in NAFLD | The FXR variant gene was transferred into the liver of FXR (−/−) mice to evaluate its effect in vivo | Correia et al. (2015) |
| Transcriptomic analysis in NAFLD | Complete transcriptome analysis of intraperitoneal adipose tissue (IAT) in severely obese adolescents was performed using RNA sequencing | Sheldon et al. (2016) |
| Alternative splicing of hepatitis B virus | The regulation of splicing of HBV in chemically and surgically induced liver injury was studied in transgenic mice with whole HBV genomes and hepatocellular carcinoma cells | Duriez et al. (2017) |
| Alternative splicing of AZIN1 in hepatitis C virus | Seven splicing variants of AZIN1 (SV2-8) were cloned from human hepatic stellate cell line LX2 by polymerase chain reaction | Paris et al. (2011) |
| The spliceosome factor SART1 in HCV | siRNA knockdown and mRNA sequencing in Huh7.5.1 cells selection genes for mRNA variation and their proteins, and HCV replication | Lin et al. (2015) |
| Transcriptome Analysis in Pediatric Hepatocellular Carcinoma | Liver samples from infants with biliary atresia were collected and transcriptome analysis was performed using RNA-seq technique | Laquaglia et al. (2016) |
| Transcriptome profiling of biliary atresia | The activity of YAP and the expression of Hippo pathway components in tumor and non-tumor liver tissues of 7 children with HCC were detected | Xiao et al. (2014) |
| Long noncoding RNA H19 (incRNAH19) in biliary atresia | Liver specimens from 53 BA patients and 11 control liver specimens were analyzed by qRT-PCR, Western blotting, histology, and immunohistochemistry (IHC) | Xiao et al. (2019) |
| Transcriptomic of human hepatocellular carcinomas and hepatoblastomas | The gene expression patterns and global genomic changes of HCC and HBS were analyzed | Luo et al. (2006) |
candidate genes among Hispanic boys (Petta et al., 2016; Petta et al., 2017; Wattacheril et al., 2017; Abul-Husn et al., 2018). Furthermore, the hepatic expression of farnesoid X receptor (FXR) was reduced in both animal models and NAFLD patients, where hepatic FXR expression was reduced in nonalcoholic steatohepatitis (NASH) (Yang et al., 2010). A study showed that FXR splicing toward FXRα2 reduced hepatic lipid accumulation through the transcriptional program, which could greatly enhance the therapeutic effect by improving pharmacological targeting of select FXR agonists (Correia et al., 2015). This evidence suggests that FXR agonists by improving pharmacological targeting of select FXR agonists program, which could greatly enhance the therapeutic effect hepatic lipid accumulation through the transcriptional level. In particular, the splicing of 3.5 KB HBV pregenomic RNA (pGRNA), which encodes either capsid or polymerase proteins to facilitate viral genome replication (Seeger and Mason, 2015).

The main HBV pGRNA splicing variant, single presplicing genomic RNA (SP1RNA), harbors a deletion of 1/3 of the viral genome and accounts for approximately 30% of the total HBV pGRNA in hosts, suggesting the importance of AS regulation in virus packaging, reverse transcription, and virus release (Terré et al., 1991; Soussan et al., 2008; Bayliss et al., 2013). In particular, host splicing factors, including SF1, hnRNPA2B, PSF, LA, and some SRSFs, have been demonstrated to participate in the splicing regulation of HBV pGRNA (Soussan et al., 2008).

With the accurate screening of blood products and organ donors, the prevalence of hepatitis C infection has been significantly reduced, and vertical transmission is the main source of infection (Della Corte et al., 2016). A single nucleotide polymorphism (SNP) variant in the antizyme-inhibitor-1 (AZIN1) gene called AZIN1 SV2 (AZIN1 splice variant 2) leads to a novel alternative spliced isoform that modifies the fibrogenic potential of hepatic stellate cells (HSCs) in HCV cirrhotic livers (Huang et al., 2007; Paris et al., 2011). Previous research indicated that the splicingosome factor SART1 (squamous cell carcinoma antigen recognized by T cells) regulates HCV replication by altering its expression and splicing level (Lin et al., 2015).

Pediatric Liver Tumors
Malignant liver tumors are rare in children, accounting for only 1% of all malignancies (Spector and Birch, 2012). While more than two-thirds of them are hepatoblastomas (HBs), 20% are hepatocellular carcinomas (HCCs). The latter section will discuss the relationship between AS and HB. Here, we only discuss AS in HCC, which is typically in older children or adolescents and is the major type of adult liver cancer (Crippa et al., 2017). At present, hepatocyte proliferation and HCC development are closely related to the transcriptional coactivator Yes-associated protein and its targeted Hippo pathway in animal models (Dong et al., 2007). Previous studies have shown that the mRNA expression of Yes-associated protein target genes (CCNE1, CTGF, Cyr61) was increased in pediatric HCC, demonstrating an enrichment of YAP nuclear localization and its activity in moderately differentiated pediatric HCC (LaQuaglia et al., 2016). However, the relationship between AS and HCC in children has rarely been reported in comparison to adult patients.

Liver Diseases Uniquely Present in Children and Their Splicing Regulation
Post-Transcriptional Regulation in Biliary Atresia
BA is caused by bile duct occlusion or interruption from the hilum to the duodenum and is becoming the most common cholestatic liver disease leading to pediatric liver transplantation. The incidence of BA ranges from 1 in 5,000 cases to 1 in 19,000 cases, with higher rates in Asia than in European countries (Fawaz et al., 2017). A number of likely causal proteins of BA have been identified in previous studies, including FOXA2 (Tsai et al., 2015), CFC1 (Davit-Spraul et al., 2008), ZEB2 (Cui et al., 2011), ZIC3 (Ware et al., 2004), HNF1B (Shaalan et al., 2019), PKD1 L1 (Berauer et al., 2019), GPC1 (Cui et al., 2011), XPNPEP1 (Garcia-Barceló et al., 2010), ADD3 (Tsai et al., 2014), EFEMP1 (Chen et al., 2018), ARF6 (Ningappa et al., 2015), STIP1, and REV1 (Rajagopalan et al., 2020), without splicing mutations (Table 2). However, no genes have been identified as a
### TABLE 2 | Genetic manipulation of RNA splicing in pediatric liver disease.

| Gene            | Related diseases                      | Splicing mutation | Potential function                                | RNA splicing or genetic variants | As potential diagnostic/therapeutic targets | References |
|-----------------|---------------------------------------|-------------------|---------------------------------------------------|----------------------------------|------------------------------------------|------------|
| ATP8B1/FIC1     | Progressive Familial Intrahepatic Cholestasis type 1 | 14 splicing mutations | exon skipping, donor, acceptor, splice sites       | Splicing mutations associated with PFIC | As novel therapeutic targets             | van der Woerd et al. (2015) |
| ABCB11/BESP     | Progressive Familial Intrahepatic Cholestasis type 2 | c.784 + 1G > C    | Splice sites                                      | Splicing mutations associated with PFIC | As diagnostic targets                   | Sharma et al. (2018) |
| ABCB4/MDR3      | Progressive Familial Intrahepatic Cholestasis type 3 | c.3487-16T>C; c.175C>T | Without mention              | Splicing mutations associated with PFIC | As diagnostic targets                   | Khabou et al. (2016) |
| TJP2            | Progressive Familial Intrahepatic Cholestasis type 4 | c.2180-5T>G       | Exon skipping                                     | Splicing mutations associated with PFIC | As diagnostic targets                   | Zhang et al. (2020) |
| MYO5B           | Progressive Familial Intrahepatic Cholestasis type 5 | c.3538-1G>A; c.2414+5G>T; c.4852 + 11A>G | Splice sites                                      | Splicing mutations associated with PFIC | As novel therapeutic targets             | Qiu et al. (2017) |
| JAG1            | Alagille syndrome                      | 49 splicing mutations include c.2917–8C > A | Exon skipping, donor, acceptor, splice sites      | Splicing mutations associated with Alagille syndrome | As diagnostic targets                   | Chen et al. (2020); (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=JAG1) |
| NOTCH2          | Alagille syndrome                      | c.5930-1G>A       | Splice acceptor                                   | Splicing mutations associated with Alagille syndrome | As diagnostic targets                   | Modanieli et al. (2006) |
| PNPLA3          | Nonalcoholic fatty liver disease       | Without mention   | Without mention                                   | Genetic variants associated with NAFLD | Uncertainty                             | Valenti et al. (2010) |
| TM6SF2          | Nonalcoholic fatty liver disease       | Without mention   | Without mention                                   | Genetic variants associated with NAFLD | Uncertainty                             | Kozlitina et al. (2014) |
| GCKR            | Nonalcoholic fatty liver disease       | Without mention   | Without mention                                   | Genetic variants associated with NAFLD | Uncertainty                             | Santoro et al. (2012) |
| MBOAT7          | Nonalcoholic fatty liver disease       | Without mention   | Without mention                                   | Genetic variants associated with NAFLD | Uncertainty                             | Mancina et al. (2016) |
| MERTK           | Nonalcoholic fatty liver disease       | Without mention   | Without mention                                   | Genetic variants associated with NAFLD | Uncertainty                             | Dongiovanni et al. (2018) |
| IFNL4           | Nonalcoholic fatty liver disease       | Without mention   | Without mention                                   | Genetic variants associated with NAFLD | Uncertainty                             | Petta et al. (2017) |
| HSD17B13        | Nonalcoholic fatty liver disease       | Without mention   | Without mention                                   | Genetic variants associated with NAFLD | Uncertainty                             | Abul-Husn et al. (2018) |
| FXR             | Nonalcoholic fatty liver disease       | FXR splicing toward FXRα2 reduced hepatic lipid accumulation through the transcriptional program | Enhance the therapeutic effect by improving pharmacological targeting of select FXR agonists | RNA splicing associated with NAFLD | As therapeutic targets                   | Correia et al. (2016); Sheldon et al. (2016) |
| ATP7B           | Wilson’s disease                       | 71 splicing mutations include c.51 + 4 A→T; c.2,121 + 3 A→G; c.2447 + 5 G→A; 1946 + 6 T→C; c.52-2,671_368del3039 | Exon skipping, acceptor, and donor splice | Exon skipping, acceptor, and donor splice site associated with WD | As diagnostic targets                   | Lovicu et al. (2009); Zappou et al. (2012); Mameli et al. (2015); Wang et al. (2018); (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ATP7B) |
| CCNE1           | Hepatocellular carcinomas              | Without mention   | mRNA expression was increased in the pediatric HCC | YAP target gene mRNA expression was increased in the pediatric HCC | Uncertainty                             | Laquaglia et al. (2016) |

(Continued on following page)
definite cause of isolated BA cases so far (Girard and Panasyuk, 2019). Nevertheless, the top 10 upregulated loci identified by transcriptome approach from BA samples, including CSRNP1, IL6R, CPB2, TTR, TD O 2, SERPINC1, C6, DHTKD1, IGFBP1, and RDH16, might deepen our understanding of the transcriptional and post-transcriptional mechanisms among BA patients (Xiao et al., 2014).

Recently, long noncoding RNAH19 (lncRNAH19) was proposed to have a positive correlation with the BA-related severity of liver fibrosis (Xiao et al., 2019). Moreover, H19, a molecular sponge of the microRNA let-7 family, activates its downstream target, high mobility group member AT-hook 2 (HMGA2), during biliary tract proliferation, suggesting its crucial role in BA bile duct cell proliferation and cholestatic liver injury. Thus, lncRNAH19 may emerge as a valuable target for early diagnosis and the development of novel therapeutic procedures for BA patients.

Furthermore, recent studies have shown that the abnormal expression of long noncoding RNA Alu-mediated p21 transcription regulator (APTR) in the liver of BA infants may be pivotal for liver fibrosis in these patients (Makhmudi et al., 2020). Moreover, potential determinants of prognosis in Kasai portal enterostomy (KPE), such as phosphoenolpyruvate carboxykinase (PCK1) and matrix metalloproteinase-7 (MMP7), were determined by RNA sequencing data (Ramachandran et al., 2019). In particular, the abundance of

| Gene    | Related diseases       | Splicing mutation | Potential function                                                                 | RNA splicing or genetic variants | As potential diagnostic/therapeutic targets | References                  |
|---------|------------------------|-------------------|-----------------------------------------------------------------------------------|---------------------------------|--------------------------------------------|------------------------------|
| CTGF    | Hepatocellular carcinomas | Without mention   | mRNA expression was increased in the pediatric HCC                               | YAP target gene mRNA expression was increased in the pediatric HCC          | Uncertainty                      | Laquaglia et al. (2016)     |
| Cyr61   | Hepatocellular carcinomas | Without mention   | mRNA expression was increased in the pediatric HCC                               | YAP target gene mRNA expression was increased in the pediatric HCC          | Uncertainty                      | Laquaglia et al. (2016)     |
| FOXA2   | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Tsai et al. (2015)          |
| CFC1    | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Davit-Spraul et al. (2008) |
| ZEB2    | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Cui et al. (2011)           |
| ZIC3    | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Ware et al. (2004)          |
| HNF1B   | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Shaaalan et al. (2019)     |
| PKD1L1  | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Berauer et al. (2019)      |
| GPC1    | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Oui et al. (2013)           |
| XPNPEP1 | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Garcia-Barcélo et al. (2010) |
| ADD3    | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Tsai et al. (2014)          |
| EFEMP1  | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Chen et al. (2018)          |
| ARF6    | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Ningappa et al. (2015)     |
| STIP1   | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Rajagopalan et al. (2020)  |
| REV1    | Biliary atresia         | Without mention   | Likely causal genes of BA                                                          | Likely causal genes of BA                                                  | Uncertainty                      | Rajagopalan et al. (2020)  |
| IncRNAH19 | Biliary atresia       | Without mention   | Suggesting its crucial role in BA bile duct cell proliferation and cholestatic liver injury | It was proposed to have a positive correlation with the BA-related severity of liver fibrosis | A valuable target for early diagnosis and the development of novel therapeutic procedures | Xiao et al. (2019) |
| CTNNB1  | Hepatoblastoma          | Without mention   | Genetic variants associated with HB                                                | Genetic variants associated with HB                                         | As therapeutic targets           | Crippa et al. (2017); Sha et al. (2019) |
MMP7 was higher in patients with failed jaundice clearance after KPE and in patients with end-stage liver disease (ESLD) than in the control group. In contrast, successful KPE treatment could induce PCK1 expression, and the abundance of PCK1 in patients with uncleared jaundice after KPE was repressed. Therefore, the abundance of MMP7 and PCK1 could be used as indicators for KPE outcome prediction and disease progression for clinicians.

### Splicing Mutation in Hepatoblastoma

Hepatoblastoma (HB) is the most common pediatric liver tumor, which typically occurs before the age of three and can be congenital (Trobaugh-Lotrario et al., 2013). The incidence of HBs has increased due to the greater numbers of premature births and infants with birth weights lower than 1,500 g (Feng et al., 2019). A β-catenin-encoding protein, CTNNB1, is the most frequently mutated HB gene, accounting for 50–90% of diagnosed HB cases (Crippa et al., 2017). Several genes, such as Spondin2, Efdl3, Glypican 3, Osteopontin, and PEG10, were highly elevated, whereas Ficolin 3 was downregulated in human HCC and HB cases (Luo et al., 2006). However, several genes, including IGF2, fibronectin, DLK1, TGFB1, MALAT1, and MIG6, were overexpressed in HB versus HCC.

HB is genetically characterized by abnormal activation of the Wnt/β-catenin signaling pathway (Sha et al., 2019). Generally, extensive evidence has suggested that mutations in the β-catenin gene exon 3 are responsible for the activation of the Wnt/β-catenin signal transduction pathway in HB. Furthermore, the accumulation of β-catenin proteins resulted from increased translocations to the nucleus and cytoplasm and is positively correlated to cancer severity. Therefore, the abundance of β-catenin and target genes from its signaling pathway can be used as diagnostic and prognostic markers for pediatric liver tumors. In addition, several research groups have proposed the therapeutic effects of HB by specific inhibition of Wnt/β-catenin pathway, through a number of post-transcriptional measures such as short interfering miRNA, RNAs (siRNA), and bioactive small molecules. Hence, the Wnt/β-catenin signaling pathway is a valuable target for the development of therapeutic measures of HB (Koch et al., 1999; Takayasu et al., 2001; Koch et al., 2005; Cairo et al., 2008; Eichenmüller et al., 2014; Sumazin et al., 2017; Sha et al., 2019). However, HB has the lowest mutation burden among all known cancer types, and the genetic determinants of HB remain to be further investigated (Gröbner et al., 2018). Less than 5 mutations per hepatoblastoma were identified by studies using whole-exome sequencing, suggesting that this low mutation frequency of HB hindered the potential targets that are responsible for HB progression (Eichenmüller et al., 2014; Jia et al., 2014; Sumazin et al., 2017).
FUTURE PERSPECTIVES

There are many types of liver diseases in children, but many of them are rare in the world population. To date, much less research has been conducted on the association between RNA splicing and liver diseases in children than in adults (Figure 1). Furthermore, specific disease types at the child stage have also been reported to have splicing regulation on their potential genomic loci. In this review article, we found that there are many studies that performed their research on pediatric NAFLD in comparison to adult cases. This might be due to the longer life span of this disease at the child stage, which will greatly impact their life (Draijer et al., 2019). It has been expected that more functional studies at the molecular level, including those associated with splicing and liver diseases in children than in adults (Draijer et al., 2019). Furthermore, specifically, most splicing mutations reported thus far lack functional studies at the molecular level, including those identified in PFIC, Alagille syndrome, and WD. Therefore, an in-depth study should be carried out to verify their roles in the corresponding diseases, evaluate the potential of these targets for drug development, and establish a noninvasive early diagnosis method. Specifically, these splicing events could be controlled by their upstream regulators, which have been demonstrated in adult and animal studies (Wu et al., 2021). Moreover, BA and HB, which occur in infancy or young children, seriously impact the health of children at this stage. Therefore, the molecular mechanism of these splicing variants in pediatric liver diseases requires further investigation.

AUTHOR CONTRIBUTIONS

SZ and M-XC designed the analysis and reviewed the content. J-LZ, Y-ZZ, and M-XC wrote the manuscript. S-SW, CJ, and SZ critically reviewed and revised the manuscript.

FUNDING

This work was supported by the Science Technology and Innovation Committee of Shenzhen (2021N062-JCYJ20210324115408023), Natural Science Foundation of Jiangsu Province (SBK20200442924), and National Natural Science Foundation of China (NSFC32001452).

REFERENCES

Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., et al. (2018). A Protein-Truncating HS17B13 Variant and Protection from Chronic Liver Disease. N. Engl. J. Med. 378, 1096–1106. doi:10.1056/nejmoa1712191
Al-Hussaini, A., Lone, K., Bashir, M. S., Alrashidi, S., Fagih, M., Alani, A., et al. (2021). ATP8B1, ABCB11, and ABCB4 Genes Defects: Novel Mutations Associated with Cholestasis with Different Phenotypes and Outcomes. J. Pediatr. 236, 113–123. doi:10.1016/j.jpeds.2021.04.040
Bayliss, J., Lim, L., Thompson, A. J. V., Desmond, P., Angas, P., Locarnini, S., et al. (2013). Hepatitis B Virus Splicing Is Enhanced Prior to Development of Hepatocellular Carcinoma. J. Hepatol. 59, 1022–1028. doi:10.1016/j.jhep.2013.06.018
Berauer, J. P., Mezzina, A. I., Okou, D. T., Sabo, A., Muzny, D. M., Gibbs, R. A., et al. (2019). Identification of Polycystic Kidney Disease 1 like 1 Gene Variants in Children with Biliary Atresia Splenic Malformation Syndrome. Hepatology 70, 899–910. doi:10.1002/hep.30515
Bull, L. N., and Thompson, R. J. (2018). Progressive Familial Intrahepatic Cholestasis. Clin. Liver Dis. 22, 657–669. doi:10.1016/j.clid.2018.06.003
Cairo, S., Armengol, C., De Reyniès, A., Wei, Y., Thomas, E., Renard, C.-A., et al. (2008). Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer. Cancer Cell 17, 471-484. doi:10.1016/j.ccr.2008.11.002
Chen, Y., Gilbert, M. A., Grochowski, C. M., Mcdrew, D., Llewellyn, J., Waisbourd-Zinnman, O., et al. (2018). A Genome-wide Association Study Identifies a Susceptibility Locus for Biliary Atresia on 2p16.1 within the Gene EFEMP1. Plos Genet. 14, e1007532. doi:10.1371/journal.pgen.1007532
Chen, Y., Liu, X., Chen, S., Zang, J., and Xu, C. (2020). Targeted Sequencing and RNA Assay Reveal a Noncanonical JAG1 Splicing Variant Causing Alagille Syndrome. Front. Genet. 10, 1363. doi:10.3389/fgene.2019.01363
Chikkuri, C. R., Sheppard, D., Ilagan, M. X. G., Holt, L. R., Abbott, F., Liang, S., et al. (2013). Structural Analysis Uncovers Lipid-Binding Properties of Notch Ligands. Cell Rep. 5, 861–867. doi:10.1016/j.celrep.2013.10.029
Correia, J. C., Massart, J., De Boer, J. F., Porsmry-Palmertz, M., Martinez-Redondo, V., Aguado, L. Z., et al. (2015). Bioenergetic Cues Shift FXR Splicing towards FXRα2 to Modulate Hepatic Lipolysis and Fatty Acid Metabolism. Mol. Metab. 4, 891–902. doi:10.1016/j.molmet.2015.09.005
Crippa, S., Ancy, P. B., Vazquez, J., Angelino, P., Rougemont, A. L., Guettier, C., et al. (2017). Mutant CTNINB 1 and Histological Heterogeneity Define Metabolic Subtypes of Hepatoblastoma. EMBO Mol. Med. 9, 1589–1604. doi:10.15252/emmm.201707814
Cui, S., Erlichman, J., Russo, P., Haber, B. A., and Matthews, R. P. (2011). Intrahepatic Biliary Anomalies in a Patient with Mowat-Wilson Syndrome Uncover a Role for the Zinc finger Homeobox Gene Zfhx1b in Vertebrate Biliary Development. J. Pediatr. Gastroenterol. Nutr. 52, 339–344. doi:10.1097/MPG.0b013e3181f2e5b
Cui, S., Leyva-Vega, M., Tsai, E. A., EauClaire, S. F., Glessner, J. T., Hakonarson, H., et al. (2013). Evidence from Human and Zebrafish that GPC1 Is a Biliary Atresia Susceptibility Gene. Gastroenterology 144, 1107–1115. doi:10.1053/j.gastro.2013.01.022
Davit-Spraul, A., Baussan, C., Hermez, E., Bernard, O., and Jacquemin, E. (2008). CFC1 Gene Involvement in Biliary Atresia with Polysplenia Syndrome. J. Pediatr. Gastroenterol. Nutr. 46, 111–112. doi:10.1097/MPG.0b013e3181788f44
Duriez, M., Mondouri, Y., Lekbby, B., Wang, H., Schnuriger, A., Redelsperger, F., et al. (2017). Alternative Splicing of Hepatitis B Virus: A Novel Virus/Host Interaction Altering Liver Immunity. J. Hepatol. 67, 687–699.
Del Rio-Moreno, M., Alors-Pérez, E., González-Rubio, S., Ferrin, G., Reyes, O., Rodríguez-Peralvarez, M., et al. (2019). Disregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. J. Clin. Endocrinol. Metab. 104, 3389–3402. doi:10.1210/jc.2019-00021
Della Corte, C., Mosca, A., Vania, A., Alterio, A., Alisi, A., and Nobili, V. (2016). Pediatric Liver Diseases: Current Challenges and Future Perspectives. Expert Rev. Gastroenterol. Hepatol. 10, 255–265. doi:10.1586/17477142.2016.1129274
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., et al. (2007). Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals. Cell 130, 1120–1133. doi:10.1016/j.cell.2007.07.019
Dongiovanni, P., Meroni, M., Mancina, R. M., Baselli, G., Rametta, R., Pelusi, S., et al. (2018). Protein Phosphatase 1 Regulatory Subunit 3B Gene Variation Protects against Hepatic Fat Accumulation and Fibrosis in Individuals at High Risk of Nonalcoholic Fatty Liver Disease. Hepatol. Commun. 2, 666–675. doi:10.1002/hep4.1192
Draijer, L., Bennings, M., and Koot, B. (2019). Pediatric NAFLD: an Overview and Recent Developments in Diagnostics and Treatment. Expert Rev. Gastroenterol. Hepatol. 13, 447–461. doi:10.1080/17474142.2019.1595589

Zhou et al.

Splicing Regulation in Pediatric Liver Diseases
Eichenmüller, S. A., Magee, J. C., Ng, V. L., Horslen, S. P., Fioravanti, V., Economides, J., et al. (2020). Society of Pediatric Liver Transplantation: Current Registry Status 2011-2018. Pediatr. Transpl. 24, e13605. doi:10.1111/petr.13605

Fawaz, R., Baumann, U., Ekonk, U., Fischer, B., Hadric, N., Mack, C. L., et al. (2017). Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr. 64, 154–168. doi:10.1097/mpg.0000000000001334

Feng, J., Polychronidis, G., Heger, U., Frongia, G., Mehrabi, A., and Hoffmann, K. (2021). Undiagnosed Liver Disease. Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Pediatr. Transpl. 6, 154–168. doi:10.1097/mpg.0000000000001334

Kbabou, B., Slaa-Sahnoun, O., Gargouri, M., Mkaour-Rebai, E., Keskes, L., Hachicha, M., et al. (2016). In Silico investigation of the Impact of Synonymous Variants in ABCB4 Gene on mRNA Stability/structure, Splicing Accuracy and Codon Usage: Potential Contribution to PBCD3 Disease. Comput. Biol. Chem. 65, 103–109. doi:10.1016/j.compbiolchem.2016.10.008

Koch, A., Denkhaus, D., Albrecht, S., Leuschner, I., Von Schweinitz, D., and Pietsch, T. (1999). Childhood Hepatoblastomas Frequently Carry a Mutated Degradation Targeting Box of the Beta-Catenin Gene. Cancer Res. 59, 269–273.

Koch, A., Waha, A., Hartmann, W., Hrychyk, A., Schütler, U., Waha, A., et al. (2005). Elevated Expression of Wnt Antagonists Is a Common Event in Hepatoblastomas. Clin. Cancer Res. 11, 4295–4304. doi:10.1158/1078-0432.ccr-04-1162

Kogan, R., and Ilagan, M. X. G. (2009). The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism. Cell 137, 216–233. doi:10.1016/j.cell.2009.03.045

Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., et al. (2014). Exome-wide Association Study Identifies a TM6SF2 Variant that Confers Susceptibility to Nonalcoholic Fatty Liver Disease. Nat. Genet. 46, 352–356. doi:10.1038/ng.2901

Laquaglia, M. I., Grijalva, J. L., Mueller, K. A., Perez-Atayde, A. R., Kim, H. B., Sadri-Vakili, G., et al. (2016). YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma. Sci. Rep. 6, 30238. doi:10.1038/srep30238

Li, J., Hua, W., Ji, C., Rui, Z., Yao, X., Xie, C., et al. (2020). Effect of the Patatin-like Phospholipase Domain Containing 3 Gene (PNPLA3) 1148M Polymorphism on the Risk and Severity of Nonalcoholic Fatty Liver Disease and Metabolic Syndromes: A Meta-Analysis of Paediatric and Adolescent Individuals. Pediatr. Obes. 15, e12615. doi:10.1111/joip.12615

Li, L., Krantz, I. D., Deng, Y., Genin, A., Banta, B. A., Collins, C. C., et al. (1997). Alagille Syndrome Is Caused by Mutations in Human Jagged1, Which Encodes a Ligand for Notch1. Nat. Genet. 16, 243–251. doi:10.1038/ng0797-243

Lin, W., Zhu, C., Hong, J., Zhao, L., Ilg, N., Fusco, D. N., et al. (2015). The Spliceosome Factor SART1 Exerts Its Anti-HCV Action through mRNA Splicing. J. Hepatol. 62, 1024–1032. doi:10.1016/j.jhep.2014.11.038

Lindsell, C. E., Shawber, C. J., Boulter, J., and Weinmaster, G. (1995). Jagged: A Mammalian Ligand that Activates Notch1. Cell 80, 909–917. doi:10.1016/0092-8675(94)90294-5

Liu, L. Y., Wang, Z. L., Wang, X. H., Zhu, Q. R., and Wang, J. S. (2010). ABCB1 Gene Mutations in Chinese Children with Progressive Intrahepatic Cholestasis and Low Gamma Glutamyltransferase. Liver Int. 30, 809–815. doi:10.1111/j.1478-3231.2009.02112.x

Lovicu, M., Lepori, M. B., Incolla, S., Dessi, V., Zappa, A., Iorio, R., et al. (2009). RNA Analysis of Consensus Sequence Splicing Mutations: Implications for the Diagnosis of Wilson Disease. Genet. Test. Mol. Biomarkers 13, 185–191. doi:10.1089/gtmb.2008.0089

Luo, J.-H., Ren, B., Keryanov, S., Tseng, G. C., Rao, U. N. M., Monga, S. P., et al. (2006). Transcriptomic and Genomic Analysis of Human Hepatocellular Carcinomas and Hepatoblastomas. Hepatology 44, 1012–1024. doi:10.1002/hep.21328

Makkhudi, M., Supanri, R., Putra, B. P., and Gunadi (2020). The Effect of APTR, Fn1 and CD113 Expressions on Liver Fibrosis in Biliary Atresia Patients. Pediatr. Surg. Int. 36, 75–79. doi:10.1007/s00383-015-04582-2

Mameli, E., Lepori, M. B., Chiappe, F., Ranucci, G., Di Dato, F., Iorio, R., et al. (2016). RNA Sequencing of Hepatoblastoma Reveals Novel Mutations and Cancer Genes in the Wnt Pathway and Ubiquitin Ligase Complex. Hepatology 60, 1686–1696. doi:10.1002/hep.27243

Montes, M., Sanford, B. L., Comiskey, D. F., and Chandler, D. S. (2019). RNA Splicing and Disease: Animal Models to Therapies. Trends Genet. 35, 68–87. doi:10.1016/j.tig.2018.10.002
and Severity of Pediatric Nonalcoholic Fatty Liver Disease. *Hepatology* 52, 1274–1280. doi:10.1002/hep.23823
Van Der Woerd, W. L., Mulder, J., Pagani, F., Beuers, U., Houwen, R. H. J., and Van De Graaf, S. F. J. (2015). Analysis of Aberrant Pre-messenger RNA Splicing Resulting from Mutations in ATP8B1 and Efficient In Vitro Rescue by Adapted U1 Small Nuclear RNA. *Hepatology* 61, 1382–1391. doi:10.1002/hep.27620
van IJzendoorn, S. C. D., Li, Q., Qiu, Y. L., Wang, J. S., and Overeem, A. W. (2020). Unequal Effects of Myosin 5B Mutations in Liver and Intestine Determine the Clinical Presentation of Low-Gamma-Glutamyltransferase Cholestasis. *Hepatology* 72, 1461–1468. doi:10.1002/hep.31430
Vitale, G., Gitto, S., Vukotic, R., Raimondi, F., and Andreone, P. (2019). Familial Intrahepatic Cholestatic New and Wide Perspectives. *Dig. Liver Dis.* 51, 922–933. doi:10.1016/j.dld.2019.04.013
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., et al. (2016). Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 310 Diseases and Injuries, 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015. *Lancet* 388, 1545–1602. doi:10.1016/S0140-6736(16)31678-6
Wang, C., Zhou, W., Huang, Y., Yin, H., Jin, Y., Jia, Z., et al. (2018). Presumed Missense and Synonymous Mutations in ATP7B Gene Cause Exon Skipping in Wilson Disease. *Liver Int.* 38, 1504–1513. doi:10.1111/liv.13754
Wang, H., Lekbaby, B., Fares, N., Augustin, J., Attout, T., Schnuriger, A., et al. (2019). Alteration of Splicing Factors’ Expression during Liver Disease Progression: Impact on Hepatocellular Carcinoma Outcome. *Hepatol. Int.* 13, 454–467. doi:10.1002/hup.21727-019-09950-7
Ware, S. M., Peng, J., Zhu, L., Fernbach, S., Colicos, S., Casey, B., et al. (2004). Identification and Functional Analysis of ZIC3 Mutations in Heterotaxy and Related Congenital Heart Defects. *Ann. J. Hum. Genet.* 74, 93–105. doi:10.1086/380998
Wattacheril, J., Lavinie, J. E., Chalasani, N. P., Guo, X., Kwon, S., Schwimmer, J., et al. (2017). Genome-Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys. *J. Pediatr.* 190, 100–107. doi:10.1016/j.jpeds.2017.08.004
Webster, N. J. G. (2017). Alternative RNA Splicing in the Pathogenesis of Liver Disease. *Front. Endocrinol.* 8, 133. doi:10.3389/fendo.2017.00133
Wu, H. L., Chen, P. J., Tu, S. J., Lin, M. H., Lai, M. Y., and Chen, D. S. (1991). Characterization and Genetic Analysis of Alternatively Spliced Transcripts of Hepatitis B Virus in Infected Human Liver Tissues and Transfected HepG2 Cells. *J. Virol.* 65, 1680–1686. doi:10.1128/jvi.65.4.1680-1686.1991
Xiao, J., Xia, S.-y., Xia, Y., Xia, Q., and Wang, X.-r. (2014). Transcriptome Profiling of Biliary Atresia from New Born Infants by Deep Sequencing. *Mol. Biol. Rep.* 41, 8063–8069. doi:10.1007/s11033-014-3704-6
Xiao, Y., Liu, R., Li, X., Gurley, E. C., Hylemon, P. B., Lu, Y., et al. (2019). Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia. *Hepatology* 70, 1658–1673. doi:10.1002/hep.30698
Yang, Z.-X., Shen, W., and Sun, H. (2010). Effects of Nuclear Receptor FXR on the Regulation of Liver Lipid Metabolism in Patients with Non-alcoholic Fatty Liver Disease. *Hepatol. Int.* 4, 741–748. doi:10.1016/j.hep.2010.09.020
Zappu, A., Lepori, M. B., Incollu, S., Dessi, V., Noli, M. C., Mameli, E., et al. (2012). Feasibility of RNA Studies on Illegitimate Transcription for Molecular Characterization of Splicing Mutations in the ATP7B Gene: a Case Report. *Mol. Cell Probes* 26, 63–65. doi:10.1016/j.mcp.2011.10.002
Zhang, J., Liu, L. L., Gong, J. Y., Hao, C. Z., Qiu, Y. L., Lu, Y., et al. (2020). TJP2 Hepatobiliary Disorders: Novel Variants and Clinical Diversity. *Hum. Mutat.* 41, 502–511. doi:10.1002/humu.23947
Zhu, R., Baker, S. S., Moylan, C. A., Abdelmalek, M. F., Guy, C. D., Zamboni, F., et al. (2016). Systematic Transcriptome Analysis Reveals Elevated Expression of Alcohol-Metabolizing Genes in NAFLD Livers. *J. Pathol.* 238, 531–542. doi:10.1002/path.4650

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.